Remove category
article thumbnail

Cell Therapies and their Legal Discontents

Bill of Health

In February, the news broke that the Food and Drug Administration (FDA) had approved a “first of its kind” new cancer therapy. Exciting as this is, cell therapies face complex regulatory schemes and various levers to the process of FDA approval. government and a private stem cell clinic in California.

FDA 111
article thumbnail

Public Health Product Hops

Bill of Health

Regulatory and patent exclusivity periods govern the timing of generic entry, and because market share and revenue is often quickly lost upon market entry of generic drugs, extending market exclusivity for any duration can be extremely profitable. My talk was titled “Legal Approaches to Ensuring Timely Generic Drug Availability.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests

Health Law Advisor

To provide more value to readers, I’ve started submitting FOIA requests for unpublished data to produce additional insights into how FDA works. And what better first topic than data on FDA responses to FOIA requests. FDA has been releasing data on its FOIA process, specifically its FOIA logs , for a few years. We were wrong.

FDA 52
article thumbnail

What Counts as a Psychedelic?

Bill of Health

It is time to talk about why we include (and exclude) particular drugs from this category. Besides grants for “psychedelic” research, the FDA just released draft guidance on considerations for psychedelic clinical investigations with an ambiguous definition of what is considered to be a “psychedelic.” cocaine ?).

FDA 191
article thumbnail

Tougher Enforcement of the Contraception Mandate on the Horizon

Compliance Now

Covered plans are required to automatically cover a least one form of contraception in each of the categories below without applying medical management. Other types of contraceptive services or products approved by the FDA must also be covered, even if they do not fall into one of the categories listed above. Medical Management.

FDA 100
article thumbnail

Summary of recent USP changes and potential pitfalls for compounders

Natalia Mazina

Because the changes are fairly recent, compounders want to know how and when they must be fully compliant, what enforcement vehicles are in the government arsenals, and what types of resources they must have to comply with the new requirements.

article thumbnail

Unpacking Averages: Assessing FDA’s Focus on Enforcing 510(K) Requirements on Imports

Health Law Advisor

A private equity client asked us recently to assess a rumor that FDA was on the warpath in enforcing the 510(k) requirement on medical devices from a particular region. Such a government initiative would significantly deter investments in the companies doing the importing. To be sure, FDA can have multiple reasons for refusing entry.

FDA 52